Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system

Journal of Biology

Volumn 7, Issue 4, 2008, Pages

  Han, Ruolan ^a   Yang, Yin M ^a   Dietrich, Joerg ^b   Luebke, Anne ^a   Mayer Pröschel, Margot ^a   Noble, Mark ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; MYELIN; 4',6 DIAMIDINO 2 PHENYLINDOLE; BROXURIDINE; INDOLE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY SYSTEM; CANCER THERAPY; CELL DAMAGE; CELL DESTRUCTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DELAYED MYELIN DESTRUCTION; DISEASE COURSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; PATHOLOGY; PRIORITY JOURNAL; STEM CELL; TRANSCRIPTION REGULATION; ACTION POTENTIAL; ANIMAL; AUDITORY NERVOUS SYSTEM; COMPARATIVE STUDY; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HUMAN; MYELIN SHEATH; NICK END LABELING; RAT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALIA;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; AUDITORY PATHWAYS; BROMODEOXYURIDINE; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM; FLUOROURACIL; HUMANS; IN SITU NICK-END LABELING; INDOLES; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; MYELIN SHEATH; RATS; STEM CELLS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 42549123787     PISSN: None     EISSN: 14754924     Source Type: Journal    
DOI: 10.1186/jbiol69     Document Type: Article

References (200)

1. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. A Stewart B Collins J Mackenzie E Tomiak S Verma C Bielajew, Psychooncology 2008 17 122 130 10.1002/pon.1210 17518411
2. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. M Inagaki E Yoshikawa Y Matsuoka Y Sugawara T Nakano T Akechi N Wada S Imoto K Murakami Y Uchitomi, Cancer 2007 109 146 156 10.1002/cncr.22368 17131349
3. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. DH Silverman CJ Dy SA Castellon J Lai BS Pio L Abraham K Waddell L Petersen ME Phelps PA Ganz, Breast Cancer Res Treat 2007 103 303 311 10.1007/s10549-006- 9380-z 17009108
4. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. A Hurria C Rosen C Hudis E Zuckerman KS Panageas MS Lachs M Witmer WG van Gorp M Fornier G D'Andrea M Moasser C Dang C Van Poznak A Hurria J Holland, J Am Geriatr Soc 2006 54 925 931 10.1111/j.1532-5415.2006.00732.x 16776787
5. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. FP Downie HG Mar Fan N Houede-Tchen Q Yi IF Tannock, Psychooncology 2006 15 921 930 10.1002/pon.1035 16477674
6. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. HG Fan N Houede-Tchen QL Yi I Chemerynsky FP Downie K Sabate IF Tannock, J Clin Oncol 2005 23 8025 8032 10.1200/JCO.2005.01. 6550 16258100
7. Cognitive impairment associated with adjuvant therapy in breast cancer. CM Bender SM Sereika SL Berga VG Vogel AM Brufsky KK Paraska CM Ryan, Psychooncology 2006 15 422 430 10.1002/pon.964 16097037
8. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. MG Falleti A Sanfilippo P Maruff L Weih KA Phillips, Brain Cogn 2005 59 60 70 10.1016/j.bandc.2005.05.001 15975700
9. Cognitive functioning in cancer patients: effect of previous treatment. CA Meyers JL Abbruzzese, Neurology 1992 42 434 436 1736178
10. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. SB Schagen FS van Dam MJ Muller W Boogerd J Lindeboom PF Bruning, Cancer 1999 85 640 650 10.1002/(SICI)1097-0142(19990201)85:3<640::AID- CNCR14>3.0.CO;2-G 10091737
11. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. V Jenkins V Shilling G Deutsch D Bloomfield R Morris S Allan H Bishop N Hodson S Mitra G Sadler E Shah R Stein S Whitehead J Winstanley, Br J Cancer 2006 94 828 834 10.1038/sj.bjc.6603029 16523200
12. Atypical hearing loss in women with breast cancer receiving adjuvant treatment. V Jenkins H Beveridge R Low S Mitra, Breast 2006 15 448 451 10.1016/j.breast.2005.06.005 16135407
13. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. BP Kreukels SB Schagen KR Ridderinkhof W Boogerd HL Hamburger FS van Dam, Breast Cancer Res Treat 2005 94 53 61 10.1007/s10549-005-7093-3 16175317
14. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. CB Brezden KA Phillips M Abdolell T Bunston IF Tannock, J Clin Oncol 2000 18 2695 2701 10894868
15. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. PK Duffner, Neurologist 2004 10 293 310 10.1097/01.nrl.0000144287.35993.96 15518596
16. Neurologic complications of chemotherapy for children with cancer. AT Reddy K Witek, Curr Neurol Neurosci Rep 2003 3 137 142 10.1007/s11910-003-0065-2 12583842
17. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. SB Schagen HL Hamburger MJ Muller W Boogerd FS van Dam, J Neurooncol 2001 51 159 165 10.1023/A:1010635229762 11386413
18. Delayed neurotoxicity in primary central nervous system lymphoma. AM Omuro LS Ben-Porat KS Panageas AK Kim DD Correa J Yahalom LM DeAngelis LE Abrey, Arch Neurol 2005 62 1595 1600 10.1001/archneur.62.10.1595 16216945
19. Neurotoxicity of cancer chemotherapy. EJ Dropcho, Semin Neurol 2004 24 419 426 10.1055/s-2004-861536 15637653
20. Neurological complications of radiotherapy and chemotherapy. F Keime-Guibert M Napolitano JY Delattre, J Neurol 1998 245 695 708 10.1007/s004150050271 9808237
21. What is the effect of systemic anticancer treatment on cognitive function? A Minisini G Atalay A Bottomley F Puglisi M Piccart L Biganzoli, Lancet Oncol 2004 5 273 282 10.1016/S1470-2045(04)01465-2 15120664
22. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. JS Wefel AE Kayl CA Meyers, Br J Cancer 2004 90 1691 1696 15150608
23. Cognitive dysfunction and subjective complaints of cancer patients: a cross-sectional study in a cancer rehabilitation centre. M Poppelreuter J Weis AK Külz O Tucha KW Lange HH Bartsch, Eur J Cancer 2004 40 43 49 10.1016/j.ejca.2003.08.001 14687788
24. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. SM Choi SH Lee YS Yang BC Kim MK Kim KH Cho, J Korean Med Sci 2001 16 328 334 11410695
25. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. MR Johnson A Hageboutros K Wang L High JB Smith RB Diasio, Clin Cancer Res 1999 5 2006 2011 10473079
26. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. ME Haykin M Gorman J van Hoff RK Fulbright JM Baehring, J Neurooncol 2006 76 153 157
27. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. A Shuper B Stark L Kornreich IJ Cohen S Aviner A Steinmetz J Stein Y Goshen I Yaniv, J Child Neurol 2000 15 573 580 10.1177/088307380001500902 11019787
28. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. A Shuper B Stark L Kornreich IJ Cohen G Avrahami I Yaniv, Isr Med Assoc J 2002 4 1050 1053 12489505
29. Intracarotid BCNU leukoencephalopathy. BK Kleinschmidt-DeMasters, Cancer 1986 57 1276 1280 10.1002/1097-0142(19860401)57:7<1276::AID- CNCR2820570703>3.0.CO;2-0 3948112
30. Leukoencephalopathy after cisplatin therapy. W Bruck E Heise RL Friede, Clin Neuropathol 1989 8 263 265 2620478
31. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. SA Castellon PA Ganz JE Bower L Petersen L Abraham GA Greendale, J Clin Exp Neuropsychol 2004 26 955 969 15742545
32. Estrogen- and tamoxifen-associated effects on brain structure and function. JL Eberling C Wu R Tong-Turnbeaugh WJ Jagust, Neuroimage 2004 21 364 371 10.1016/j.neuroimage.2003.08.037 14741674
33. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. DH Silverman CJ Dy SA Castellon J Lai BS Pio L Abraham K Waddell L Petersen ME Phelps PA Ganz, Breast Cancer Res Treat 2007 103 303 311 10.1007/s10549-006- 9380-z 17009108
34. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. V Jenkins V Shilling L Fallowfield A Howell S Hutton, Psychooncology 2004 13 61 66 10.1002/pon.709 14745746
35. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. A Paganini-Hill LJ Clark, Breast Cancer Res Treat 2000 2000 165 176 10.1023/A:1006426132338
36. The effects of hormone therapy on cognition in breast cancer. V Shilling V Jenkins L Fallowfield T Howell, J Steroid Biochem Molec Biol 2003 86 405 412 10.1016/j.jsbmb.2003.07.001 14623538
37. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. SA Castellon DH Silverman PA Ganz, Breast Cancer Res Treat 2005 92 199 206 10.1007/s10549-005-5342-0 16155790
38. Late effects of treatment on the intelligence of children with posterior fossa tumors. PK Duffner ME Cohen PRM Thomas, Cancer 1983 51 233 237 10.1002/1097-0142(19830115)51:2<233::AID-CNCR2820510211>3.0.CO;2-8 6821813
39. Medulloblastoma in childhood. Survival and functional results. JF Hirsch D Renier P Czernichow L Benveniste A Pierre-Kahn, Acta Neurochirurgica 1979 48 1 15 10.1007/BF01406016 495234
40. Advantages of 'total' resection of medulloblastoma and disadvantages of full head postoperative radiation therapy. AJ Raimondi T Tomita, Childs Brain 1979 5 550 551
41. Prospective intellectual testing in children with brain tumors. PK Duffner ME Cohen MS Parker, Ann Neurol 1988 23 575 579 10.1002/ana.410230608 3408238
42. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2 year results. RJ Packer LN Sutton TE Atkins J Radcliffe GR Bunin G D'Angio KR Siegel L Schut, J Neurosurg 1989 70 707 713 2709111
43. Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. RJ Packer J Goldwein HS Nicholson LG Vezina JC Allen MD Ris K Muraszko LB Rorke WM Wara BH Cohen JM Boyett, J Clin Oncol 1999 17 2127 2136 10561268
44. Effects of different forms of central nervous prophylaxis on neuropsychologic function in childhood leukemia. JH Rowland OJ Glidewell RF Sibley JC Holland R Tull A Berman ML Brecher M Harris AS Glickman E Forman, J Clin Oncol 1984 2 1327 1335 6595350
45. Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Peylan-Ramu DG Poplack PA Pizzo BT Adornato G DiChiro, N Engl J Med 1978 298 815 818 273143
46. CT abnormalities and altered methotrexate clearance in children with CNS leukemia. PK Duffner ME Cohen ML Brecher P Berger KL Parthasarathy S Bakshi LJ Ettinger A Freeman, Neurology 1984 34 229 233 6538016
47. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. RK Mulhern SL Palmer WE Reddick JO Glass LE Kun J Taylor J Langston A Gajjar, J Clin Oncol 2001 19 472 479 11208841
48. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. MS Brown SM Stemmer JH Simon JC Stears RB Jones PJ Cagnoni JL Sheeder, Am J Neuroradiol 1998 19 217 221 9504468
49. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. SM Stemmer JC Stears BS Burton RB Jones JH Simon, Am J Neuroradiol 1994 15 1267 1273 7976937
50. 5-Fluorouracil neurotoxicity. DH Moore WCJ Fowler LS Crumpler, Gynecol Oncol 1990 36 152 154 10.1016/0090-8258(90)90127-7 2295446
51. Neurotoxicity secondary to antineoplastic drugs. MK Tuxen SW Hansen, Cancer Treat Rev 1994 20 191 214 10.1016/0305-7372(94)90027-2 8156541
52. Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature. HA Bygrave JI Geh Y Jani R Glynne-Jones, Clin Oncol (R Coll Radiol) 1998 10 334 336 9848338
53. Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report. TC Chen DR Hinton L Leichman RD Atkinson ML Apuzzo WT Couldwell, Neurosurgery 1994 35 1138 1142 7885561
54. Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature. N Cossaart KS SantaCruz D Preston P Johnson BS Skikne, Bone Marrow Transplant 2003 31 57 60 10.1038/sj.bmt.1703768 12621508
55. Cerebral demyelination with 5-fluorouracil and levamisole. AB Fassas AM Gattani S Morgello, Cancer Invest 1994 12 379 383 10.3109/07357909409038226 8032957
56. Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging. C Fujimoto K Ito S Iwasaki K Nakao M Sugasawa, Otol Neurotol 2006 27 716 719 10.1097/01.mao.0000194815.15298.8b 16691149
57. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. CC Hook DW Kimmel LK Kvols BW Scheithauer PA Forsyth J Rubin CG Moertel M Rodriguez, Ann Neurol 1992 31 262 267 10.1002/ana.410310306 1637134
58. 5-FU-induced acute leukoencephalopathy. S Ishibashi H Nishimura H Mizusawa, Intern Med 2004 43 1009 1010 10.2169/internalmedicine.43.1009 15575259
59. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. ZH Israel A Lossos V Barak D Soffer T Siegal, Acta Oncol 2000 39 117 120 10.1080/028418600431085 10752665
60. Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. DW Kimmel AJ Schutt, Mayo Clin Proc 1993 68 363 365 8455395
61. The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. WA Bleeker NH Mulder J Hermans R Otter JT Plukker, Ann Oncol 2000 11 547 552 10.1023/A:1008351312879 10907947
62. Multifocal inflammatory leukoencephalopathy developing in a patient receiving 5-fluorouracil and levamisole. P Critchley R Abbott FJ Madden, Clin Oncol (R Coll Radiol) 1994 6 406 7873488
63. Neuroradiology case of the day. Multifocal inflammatory leukoencephalopathy due to treatment with 5-fluorouracil and levamisole. DS Enterline NC Davey RD Tien, Am J Roentgenol 1995 165 214 215
64. Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. AT Figueredo SE Fawcet DW Molloy J Dobranowski JE Paulseth, Cancer Invest 1995 13 608 611 10.3109/07357909509024930 7583711
65. 5-Fluorouracil- and levamisole-associated multifocal leukoencephalopathy. G Galassi G Tassone M Sintini M Spagnoli L Bertolani L Mavilla, Eur Neurol 1996 36 244 246 10.1159/000117263 8814435
66. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. G Luppi A Zoboli F Barbieri G Crisi L Piccinini V Silingardi, Ann Oncol 1996 7 412 415 8805935
67. Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer. CL Murray WJ Ford KK Swenson D Heros PW Sperduto, Am J Neuroradiol 1997 18 1591 1592 9296206
68. Multifocal inflammatory leukencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon. IS Neu, Acta Neurol Scand 1993 87 70 8424316
69. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis - a case report. DM Savarese J Gordon TW Smith NS Litofsky R Licho R Ragland L Recht, Cancer 1996 77 387 394 10.1002/(SICI)1097-0142(19960115)77: 2<387::AID-CNCR23>3.0.CO;2-X 8625249
70. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. W Scheithauer GV Kornek A Marczell J Karner G Salem R Greiner D Burger F Stoger J Ritschel E Kovats HM Vischer B Schneeweiss D Depisch, Br J Cancer 1998 77 1349 1354 9579845
71. Diffusion-weighted magnetic resonance imaging in early stage of 5-fluorouracil-induced leukoencephalopathy. KK Tha S Terae M Sugiura T Nishioka M Oka K Kudoh K Kaneko K Miyasaka, Acta Neurol Scand 2002 106 379 386 10.1034/j.1600-0404.2002.01253.x 12460146
72. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. VC Wu JW Huang HC Lien ST Hsieh HM Liu CC Yang YH Lin JJ Hwang KD Wu, Medicine (Baltimore) 2006 85 203 213 10.1097/01.md.0000230250.95281.60 16862045
73. Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy. A Fujikawa K Tsuchiya S Katase Y Kurosaki J Hachiya, Eur Radiol 2001 11 2602 2606 10.1007/s003300100955 11734966
74. Multifocal inflammatory leukoencephalopathy: use of thallium-201 SPECT and proton MRS. YH Hwang CK Suh SP Park, J Korean Med Sci 2003 18 621 624 12923348
75. A case of neurotoxicity following 5-fluorouracil-based chemotherapy. SS Ki JM Jeong SH Kim SH Jeong JH Lee CJ Han YC Kim JO Lee YJ Hong, Korean J Intern Med 2002 17 73 77 12014219
76. Leukoencephalopathy following chemotherapy for colonic carcinoma. W Mak PW Cheng RT Cheung, Clin Radiol 2001 56 333 335 10.1053/crad.1999.0278 11286589
77. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. S Ohara R Hayashi S Hata N Itoh N Hanyu K Yamamoto, Acta Neuropathol 1998 96 527 531 9829818 10.1007/s004010050929
78. Fluorouracil-induced neurotoxicity. NA Pirzada II Ali RM Dafer, Ann Pharmacother 2000 34 35 38 10.1345/aph.18425 10669184
79. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Dietrich R Han Y Yang M Mayer-Pröschel M Noble, J Biol 2006 5 22 17125495 10.1186/jbiol50
80. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. RS Bourke CR West G Chheda DB Tower, Cancer Res 1973 33 1735 1746 4198466
81. Clinical pharmacology of 5-fluorouracil. RB Diasio BE Harris, Clin Pharmacokinet 1989 16 215 237 10.2165/00003088-198916040-00002 2656050
82. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. BJ McDermott HW van den Berg RF Murphy, Cancer Chemother Pharmacol 1982 9 173 178 10.1007/BF00257748 7160054
83. Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. E Fournier C Passirani A Vonarbourg L Lemaire N Colin S Sagodira P Menei JP Benoit, Int J Pharm 2003 268 31 35 10.1016/j.ijpharm. 2003.08.014 14643974
84. Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. E Fournier C Passirani C Montero-Menei N Colin P Breton S Sagodira P Menei JP Benoit, Cancer 2003 97 2822 2829 10.1002/cncr.11388 12767096
85. Multipotent and restricted precursors in the central nervous system. MS Rao, Anat Rec 1999 257 137 148 10.1002/(SICI)1097-0185(19990815)257:4<137:: AID-AR7>3.0.CO;2-Q 10467245
86. Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells. M Mayer-Pröschel A Kalyani T Mujtaba MS Rao, Neuron 1997 19 773 785 10.1016/S0896-6273(00)80960-5 9354325
87. Glial restricted precursors are derived from multipotent neuroepithelial stem cells. M Rao M Mayer-Pröschel, Dev Biol 1997 188 48 63 10.1006/dbio.1997.8597 9245511
88. A tripotential glial precursor cell is present in the developing spinal cord. M Rao M Noble M Mayer-Pröschel, Proc Natl Acad Sci USA 1998 95 3996 4001 9520481 10.1073/pnas.95.7.3996
89. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on the culture medium. MC Raff RH Miller M Noble, Nature 1983 303 390 396 10.1038/303390a0 6304520
90. WAF-1) and anti-apoptotic protein (bcl-2) in breast cancer cells. LW Chow WT Loo, Breast Cancer Res Treat 2003 80 239 244 10.1023/A:1024995202135 14503796
91. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. DB Longley WL Allen U McDermott TR Wilson T Latif J Boyer M Lynch PG Johnston, Clin Cancer Res 2004 10 3562 3571 10.1158/1078-0432.CCR-03-0532 15161716
92. Evidence for the existence of at least two timing mechanisms that contribute to oligodendrocyte generation in vitro. N Ibarrola M Mayer-Pröschel A Rodriguez-Pena M Noble, Dev Biol 1996 180 1 21 10.1006/dbio.1996.0280 8948570
93. Oligodendrocyte precursor cells from different brain regions express divergent properties consistent with the differing time courses of myelination in these regions. J Power M Mayer-Pröschel J Smith M Noble, Dev Biol 2002 245 362 375 10.1006/dbio.2002.0610 11977987
94. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. J Smith E Ladi M Mayer-Pröschel M Noble, Proc Natl Acad Sci USA 2000 97 10032 10037 10944195 10.1073/pnas.170209797
95. Transient expression of doublecortin during adult neurogenesis. JP Brown S Couillard-Despres CM Cooper-Kuhn J Winkler L Aigner HG Kuhn, J Comp Neurol 2003 467 1 10 10.1002/cne.10874 14574675
96. Subventricular zone astrocytes are neural stem cells in the adult mammalian. F Doetsch I Caille DA Lim JM Garcia-Verdugo A Alvarez-Buylla, Cell 1999 97 703 716 10.1016/S0092-8674(00)80783-7 10380923
97. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. SP Fancy C Zhao RJ Franklin, Mol Cell Neurosci 2004 27 247 254 15519240
98. Endogenous Nkx2.2+/Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. JF Talbott DN Loy Y Liu MS Qiu MB Bunge MS Rao SR Whittemore, Exp Neurol 2005 192 11 24 10.1016/j.expneurol.2004.05.038 15698615
99. Neurogenesis in adult subventricular zone. A Alvarez-Buylla JM Garcia-Verdugo, J Neurosci 2002 22 629 634 11826091
100. Roles of the mammalian subventricular zone in cell replacement after brain injury. MJ Romanko R Rola JR Fike FG Szele ML Dizon RJ Felling CY Brazel SW Levison, Prog Neurobiol 2004 74 77 99 10.1016/j.pneurobio.2004.07.001 15518954
101. Transcription factor co-expression patterns indicate heterogeneity of oligodendroglial subpopulations in adult spinal cord. M Kitada DH Rowitch, Glia 2006 54 35 46 10.1002/glia.20354 16673374
102. Insights into ototoxicity. Analogies to nephrotoxicity. HD Humes, Ann NY Acad Sci 1999 884 15 18 10842580
103. Cisplatin. EE Trimmer JM Essigmann, Essays Biochem 1999 34 191 121 10730196
104. Auditory brain stem response in neuropathological mutant mice (shiverer and reeler). J Kanzaki K Mikoshiba Y Tsukada, ORL J Otorhinolaryngol Relat Spec 1985 47 294 298 4080337
105. Cochlear nerve demyelination causes prolongation of wave I latency in ABR of the myelin deficient (md) rat. T Ito M Tokuriki Y Shibamori T Saito Y Nojyo, Hear Res 2004 191 119 124 10.1016/j.heares.2003.12.019 15109711
106. Iron deficiency anemia in infancy: long-lasting effects on auditory and visual system functioning. C Algarin P Peirano M Garrido F Pizarro B Lozoff, Pediatr Res 2003 53 217 223 10.1203/01.PDR.0000047657.23156.55 12538778
107. Auditory brainstem response in children with iron deficiency anemia. H Cankaya AF Oner E Egeli H Caksen A Uner G Akcay, Acta Paediatr Taiwan 2003 44 21 24 12800379
108. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. M Roncagliolo M Garrido T Walter P Peirano B Lozoff, Am J Clin Nutr 1998 68 683 690 9734748
109. Brainstem auditory evoked potential responses in iron deficient anemic children. N Shankar OP Tandon R Bandhu N Madan S Gomber, Indian J Physiol Pharmacol 2000 44 297 303 10941617
110. Restoration of brain stem auditory-evoked potentials by gene transfer in shiverer mice. T Fujiyoshi L Hood TJ Yoo, Ann Otol Rhinol Laryngol 1994 103 449 456 7515606
111. Progressive deterioration of central components of auditory brainstem responses during post-natal development of the myelin mutant taiep rat. M Roncagliolo J Benitez JR Eguibar, Audiol Neurootol 2000 5 267 275 10.1159/000013891 10899697
112. In vivo analysis of oligodendrocyte lineage development in postnatal FGF2 null mice. JC Murtie YX Zhou TQ Le RC Armstrong, Glia 2005 49 542 554 10.1002/glia.20142 15578654
113. The radioresponse of the central nervous system: a dynamic process. PJ Tofilon JR Fike, Radiat Res 2000 153 357 370 10.1667/0033-7587(2000)153[0357: TROTCN]2.0.CO;2 10798963
114. Late effects of radiation are due principally to vascular damage in tissue. JW Hopewell HR Withers, Med Phys 1998 25 2265 2269 10.1118/1.598455 9874816
115. Irradiation induces neural precursor-cell dysfunction. ML Monje S Mizumatsu FR Fike TD Palmer, Nat Med 2002 8 955 962 10.1038/nm749 12161748
116. Inflammatory blockade restores adult hippocampal neurogenesis. ML Monje H Toda TD Palmer, Science 2003 302 1760 1765 10.1126/science.1088417 14615545
117. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. JM Austyn S Gordon, Eur J Immunol 1981 11 805 815 10.1002/eji.1830111013 7308288
118. Platelet/endothelial cell adhesion molecule-1 (PECAM-1) expression by human brain microvessel endothelial cells in primary culture. D Wong K Dorovini-Zis, Brain Res 1996 731 217 220 10.1016/0006-8993(96)00673-7 8883874
119. 5-fluorouracil-induced oligodendrocyte death and inhibitory effect of cycloheximide, Trolox, and Z-VAD-FMK in murine cortical culture. KH Cho SM Choi BC Kim SH Lee MS Park MK Kim JK Kim, Cancer 2004 100 1484 1490 10.1002/cncr.20114 15042683
120. In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. M Yamada H Nakagawa M Fukushima K Shimizu T Hayakawa K Ikenaka, J Neurooncol 1998 37 115 121 10.1023/A:1005869226496 9524089
121. The phosphoinositide/protein kinase C system as a target for neurotoxicity. LG Costa, Pharmacol Res 1990 22 393 408 10.1016/1043-6618(90) 90747-2 2169611
122. Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer. S Ohnoa M Toi K Kuroi S Nakamura H Iwata M Kusama N Masuda K Yamazaki K Hisamatsu Y Sato Y Takatsuka E Shin H Kaise M Kurozumi H Tsuda F Akiyama, Biomed Pharmacother 2005 59 Suppl 2 S323 S324 10.1016/S0753-3322(05)80063-0 16507401
123. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. A Hackshaw A Knight P Barrett-Lee R Leonard, Br J Cancer 2005 93 1215 1221 10.1038/sj.bjc.6602858 16278665
124. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. M Trudeau F Charbonneau K Gelmon K Laing J Latreille J Mackey D McLeod K Pritchard L Provencher S Verma, Lancet Oncol 2005 6 886 898 10.1016/S1470-2045(05)70424-1 16257797
125. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. M Martin A Villar A Sole-Calvo R Gonzalez B Massuti J Lizon C Camps A Carrato A Casado MT Candel J Albanell J Aranda B Munarriz J Campbell E Diaz-Rubio GEICAM Group (Spanish Breast Cancer Research Group), Spain, Ann Oncol 2003 14 833 842 10.1093/annonc/mdg260 12796019
126. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multi-center study. P Therasse L Mauriac M Welnicka-Jaskiewicz P Bruning T Cufer H Bonnefoi E Tomiak KI Pritchard A Hamilton MJ Piccart, J Clin Oncol 2003 21 843 850 10.1200/JCO.2003.05.135 12610183
127. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. V Valero AU Buzdar M McNeese E Singletary GN Hortobagyi, Clin Breast Cancer 2002 3 Suppl 2 S63 S68 12435294
128. Chemotherapy for breast cancer brain metastases. MH Fenner K Possinger, Onkologie 2002 25 474 479 10.1159/000067443 12415203
129. Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer. H Yoshizawa J Tanaka H Kagamu Y Maruyama H Miyao K Ito T Sato A Iwashima E Suzuki F Gejyo, Br J Cancer 2003 89 803 807 10.1038/sj.bjc.6601227 12942108
130. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. W Ichikawa, Gastric Cancer 2006 9 145 155 10.1007/s10120-006-0373-8 16952032
131. The role of chemotherapy in patients with established gastric cancer. AD Wagner PM Schneider WE Fleig, Best Pract Res Clin Gastroenterol 2006 20 789 799 10.1016/j.bpg.2006.01.002 16997160
132. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. SR Park JH Chun YW Kim JH Lee IJ Choi CG Kim JS Lee JM Bae HK Kim, Am J Clin Oncol 2005 28 433 438 10.1097/01.coc.0000162424.69631.79 16199979
133. Gastric cancer. Treatment of advanced disease and new drugs. F Caponigro G Facchini G Nasti RV Iaffaioli, Front Biosci 2005 10 3122 3126 10.2741/1768 15970566
134. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. A Ohtsu, Gastric Cancer 2005 8 95 102 10.1007/s10120-005-0324-9 15864716
135. Clinical overview: adjuvant therapy of gastrointestinal cancer. JS Macdonald, Cancer Chemother Pharmacol 2004 54 Suppl 1 S4 S11 15309508
136. Systemic treatment of gastric cancer. JL Dickson D Cunningham, Eur J Gastroenterol Hepatol 2004 16 255 263 10.1097/00042737-200403000-00003 15195888
137. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. A Sultana CT Smith D Cunningham N Starling JP Neoptolemos P Ghaneh, J Clin Oncol 2007 25 2607 2615 10.1200/JCO.2006.09.2551 17577041
138. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. S Krishnan V Rana NA Janjan GR Varadhachary JL Abbruzzese P Das ME Delclos MS Gould DB Evans RA Wolff CH Crane, Cancer 2007 110 47 55 10.1002/cncr.22735 17538975
139. Treatment of advanced pancreatic cancer. M Ducreux V Boige D Malka, Semin Oncol 2007 34 2 Suppl 1 S25 S30 10.1053/j.seminoncol.2007.01.006 17449349
140. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. JK Park JK Ryu JK Lee WJ Yoon SH Lee YT Kim YB Yoon, Pancreas 2006 33 397 402 10.1097/01.mpa.0000236725.26672.be 17079946
141. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. T Okusaka H Ishii A Funakoshi H Ueno J Furuse T Sumii, Jpn J Clin Oncol 2006 36 557 563 10.1093/jjco/hyl067 16870696
142. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. A Khanna GR Walker AS Livingstone KL Arheart C Rocha-Lima LG Koniaris, J Gastrointest Surg 2006 10 689 697 10.1016/j.gassur.2005.11.006 16713541
143. A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. W Heim GL Wampler JJ Lokich HD Brereton SJ Scialla F LaLuna JD Ahlgren J Nevin JG Fryer D Alt, J Clin Oncol 1991 9 2162 2166 1660065
144. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. S Matsumoto T Igishi K Hashimoto M Kodani Y Shigeoka H Nakanishi H Touge J Kurai H Makino K Takeda K Yasuda Y Hitsuda E Shimizu, Int J Oncol 2004 25 1311 1318 15492820
145. Cerebellar toxicity with high-dose cytosine arabinoside. RH Herzig JD Hines GP Herzig SN Wolff PA Cassileth HM Lazarus DJ Adelstein RA Brown PF Coccia S Strandjord, J Clin Oncol 1987 5 927 932 3585447
146. Central nervous system effects of high-dose cytosine arabinoside. RH Herzig GP Herzig SN Wolff JD Hines JW Fay GL Phillips, Semin Oncol 1987 14 21 24 3589694
147. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. SB Schagen MJ Muller W Boogerd GJ Mellenbergh FS van Dam, J Natl Cancer Inst 2006 98 1742 1745 17148777
148. Neurological complications of antineoplastic therapy. WR Shapiro DF Young, Acta Neurol Scand Suppl 1984 100 125 132 6385604
149. Cognitive effects of standard-dose chemotherapy in patients with cancer. TA Ahles A Saykin, Cancer Invest 2001 19 812 820 10.1081/CNV-100107743 11768035
150. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. TA Ahles AJ Saykin CT Furstenberg B Cole LA Mott IK Skalla MB Whedon S Bivens T Mitchell ER Greenberg PM Silberfarb, J Clin Oncol 2002 20 485 493 10.1200/JCO.20.2.485 11786578
151. Neurocognitive dysfunction in cancer patients. CA Meyers, Oncology 2000 14 75 79 10680150
152. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. KA Phillips J Bernhard, J Natl Cancer Inst 2003 95 190 197 12569140
153. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. RA Price PA Jamieson, Cancer 1975 35 306 318 10.1002/1097-0142(197502)35:2<306::AID-CNCR2820350203>3.0.CO;2-J 1089469
154. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. FS van Dam SB Schagen MJ Muller W Boogerd E vd Wall ME Droogleever Fortuyn S Rodenhuis, J Natl Cancer Inst 1998 90 210 218 10.1093/jnci/90.3.210 9462678
155. Changes observed in multiple sclerosis using magnetic resonance imaging reflect a focal pathology distributed along axonal pathways. DL Arnold, J Neurol 2005 252 Suppl 5 v25 v29 10.1007/s00415-005-5005-4 16254698
156. Assessing treatment effects on axonal loss - evidence from MRI monitored clinical trials. F Barkhof, J Neurol 2004 251 Suppl 4 iv6 iv12 15378302
157. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. C Bjartmar JR Wujek BD Trapp, J Neurol Sci 2003 206 165 171 10.1016/S0022-510X(02)00069-2 12559505
158. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. W Bruck, J Neurol 2005 252 Suppl 5 v3 v9 10.1007/s00415-005-5002-7 16254699
159. Axon pathology in neurological disease: a neglected therapeutic target. MP Coleman VH Perry, Trends Neurosci 2002 25 532 537 10.1016/S0166-2236(02) 02255-5 12220882
160. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. SL Hauser JR Oksenberg, Neuron 2006 52 61 76 10.1016/j.neuron.2006.09.011 17015227
161. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. T Owens, Curr Opin Neurol 2003 16 259 265 10.1097/00019052-200306000-00003 12858060
162. Prospects for neuroprotection in multiple sclerosis. VW Yong, Front Biosci 2004 9 864 872 10.2741/1276 14766415
163. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. R Okeda M Shibutani T Matsuo T Kuroiwa R Shimokawa T Tajima, Acta Neuropathol (Berl) 1990 81 66 73 10.1007/BF00662639
164. Metabolites of 5-fluorouracil, α-fluoro-β-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. T Akiba R Okeda T Tajima, Acta Neuropathol (Berl) 1996 92 8 13 10.1007/s004010050482
165. Intrathecal 5-fluoro-2'-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. H Nakagawa M Yamada M Fukushima K Ikenaka, Cancer Chemother Pharmacol 1999 43 247 256 10.1007/s002800050891 9923556
166. Cisplatin and platinum drugs at the molecular level. T Boulikas M Vougiouka, Oncol Rep 2003 10 1663 1682 14534679
167. Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. DL Ding J Wang R Salvi D Henderson BH Hu SL McFadden M Mueller, Ann N Y Acad Sci 1999 884 152 170 10.1111/j.1749-6632.1999.tb08640.x 10842592
168. Application of antioxidants and other agents to prevent cisplatin ototoxicity. LP Rybak C Whitworth S Somani, Laryngoscope 1999 109 1740 1744 10.1097/00005537-199911000-00003 10569399
169. Mechanisms of cisplatin-induced ototoxicity and prevention. LP Rybak CA Whitworth D Mukherjea V Ramkumar, Hear Res 2007 226 157 167 10.1016/j.heares. 2006.09.015 17113254
170. The cochleovestibular system/ototoxicity/clinical issues. A Shulman, Ann N Y Acad Sci 1999 884 433 436 10.1111/j.1749-6632.1999.tb08660.x 10842612
171. Future opportunities in preventing cisplatin induced ototoxicity. JH van den Berg JH Beijnen AJ Balm JH Schellens, Cancer Treat Rev 2006 32 390 397 10.1016/j.ctrv.2006.04.011 16781082
172. Auditory brainstem response in children with iron deficiency anemia. H Cankaya AF Oner E Egeli H Caksen A Uner G Akcay, Acta Paediatr Taiwan 2003 44 21 24 12800379
173. Maturational time course for the ABR in preterm and full term infants. JJ Eggermont A Salamy, Hear Res 1988 33 35 47 10.1016/0378-5955(88)90019-6 3372369
174. Influences of birthweight upon brainstem maturation as reflected by auditory brainstem response (ABR) evaluation. G Paludetti F Ottaviani G Almadori C Cagini F Pierri M Maurizi, Int J Pediatr Otorhinolaryngol 1987 13 77 84 3623812 10.1016/0165-5876(87)90010-3
175. Abnormal auditory brainstem response among infants with prenatal cocaine exposure. MA Tan-Laxa C Sison-Switala W Rintelman EMJ Ostrea, Pediatrics 2004 113 357 360 10.1542/peds.113.2.357 14754949
176. Epigenetic memory loss in aging oligodendrocytes in the corpus callosum. S Shen A Liu J Li C Wolubah P Casaccia-Bonnefil, Neurobiol Aging 2008 29 452 463 10.1016/j.neurobiolaging.2006.10.026 17182153
177. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. G Bartzokis JL Cummings D Sultzer VW Henderson KH Nuechterlein J Mintz, Arch Neurol 2003 60 393 398 10.1001/archneur.60.3.393 12633151
178. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. G Bartzokis, Neurobiol Aging 2004 25 5 18 10.1016/j.neurobiolaging.2003.03.001 14675724
179. Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. D Head RL Buckner JS Shimony LE Williams E Akbudak TE Conturo M McAvoy JC Morris AZ Snyder, Cereb Cortex 2004 14 410 423 10.1093/cercor/bhh003 15028645
180. Diffusion tensor imaging of adult age differences in cerebral white matter: relation to response time. DJ Madden WL Whiting SA Huettel LE White JR MacFall JM Provenzale, Neuroimage 2004 21 1174 1181 10.1016/j.neuroimage.2003. 11.004 15006684
181. Marked loss of myelinated nerve fibers in the human brain with age. L Marner JR Nyengaard Y Tang B Pakkenberg, J Comp Neurol 2003 462 144 152 10.1002/cne.10714 12794739
182. Age-related white matter atrophy in the human brain. W Meier-Ruge J Ulrich M Bruhlmann E Meier, Ann N Y Acad Sci 1992 673 260 269 10.1111/j.1749-6632.1992.tb27462.x 1485724
183. The effects of normal aging on myelin and nerve fibers: a review. A Peters, J Neurocytol 2002 31 581 593 10.1023/A:1025731309829 14501200
184. Aging and the myelinated fibers in prefrontal cortex and corpus callosum of the monkey. A Peters C Sethares, J Comp Neurol 2002 442 277 291 10.1002/cne.10099 11774342
185. Age-related changes in prefrontal white matter measured by diffusion tensor imaging. DH Salat DS Tuch ND Hevelone B Fischl S Corkin HD Rosas AM Dale, Ann N Y Acad Sci 2005 1064 37 49 10.1196/annals.1340.009 16394146
186. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor Imaging. J Abraham MW Haut MT Moran S Filburn1 S Lemiuex H Kuwabara, Clin Breast Cancer 2008 8 88 91
187. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. JS Wefel R Lenzi RL Therlault RN Davis CA Meyers, Cancer 2004 100 2292 2299 10.1002/cncr.20272 15160331
188. Cisplatin-induced non-convulsive encephalopathy. O Lyass A Lossos A Hubert M Gips T Peretz, Anticancer Drugs 1998 9 100 104 10.1097/00001813- 199801000-00013 9491799
189. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. RG Mignone ET Weber, Brain Res 2006 1111 26 29 10.1016/j.brainres.2006.06.093 16879810
190. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. EJ Freireich EA Gehan DP Rall LH Schmidt HE Skipper, Cancer Chemother Rep 1966 50 219 244 4957125
191. Expression of exposure in negative carcinogenicity studies: dose/body weight, dose/body surface area, or plasma concentrations? A Monro J Mordenti, Toxicol Pathol 1995 23 187 198 7569674
192. First-time-in-human dose selection: allometric thoughts and perspectives. H Boxenbaum C DiLea, J Clin Pharmacol 1995 35 957 966 8568013
193. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. EM Voisin M Ruthsatz JM Collins PC Hoyle, Regul Toxicol Pharmacol 1990 12 107 116 10.1016/S0273-2300(05)80052-2 2259752
194. Dosage regimen design for pharmaceutical studies conducted in animals. J Mordenti, J Pharm Sci 1986 75 852 857 10.1002/jps.2600750906 3465954
195. Combined 5-fluorouracil/systemic interferon-β gene therapy results in long-term survival in mice with established colorectal liver metastases. EA Choi H Lei DJ Maron R Mick J Barsoum QC Yu DL Fraker JM Wilson FR Spitz, Clin Cancer Res 2004 10 1535 1544 10.1158/1078-0432.CCR-0040-03 14977858
196. Effect of human recombinant granulocyte colony-stimulating factor on hematopoietic injury in mice induced by 5-fluorouracil. M Shimamura Y Kobayashi A Yuo A Urabe T Okabe Y Komatsu S Itoh F Takaku, Blood 1987 69 353 355 3491641
197. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. H Akbulut Y Tang J Maynard L Zhang G Pizzorno A Deisseroth, Clin Cancer Res 2004 10 7738 7746 10.1158/1078-0432.CCR-04-0490 15570008
198. Efferent protection from acoustic injury is mediated via α9 nicotinic acetylcholine receptors on outer hair cells. SF Maison AE Luebke MC Liberman J Zuo, J Neurosci 2002 22 10838 10846 12486177
199. Getting a GR(i)P on oligodendrocyte development. M Noble C Pröschel M Mayer-Pröschel, Dev Biol 2004 265 33 52 10.1016/j.ydbio.2003.06.002 14697351
200. An 'oligarchy' rules neural development. DH Rowitch RQ Lu N Kessaris WD Richardson, Trends Neurosci 2002 25 417 422 10.1016/S0166-2236(02)02201-4 12127759